MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
15.53
+0.15
+0.98%
Pre Market: 14.50 -1.03 -6.63% 09:01 03/31 EDT
OPEN
15.45
PREV CLOSE
15.38
HIGH
16.01
LOW
15.29
VOLUME
513
TURNOVER
0
52 WEEK HIGH
25.77
52 WEEK LOW
3.500
MARKET CAP
1.24B
P/E (TTM)
-33.3978
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GLUE last week (0323-0327)?
Weekly Report · 1d ago
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Reuters · 1d ago
MONTE ROSA THERAPEUTICS INC <GLUE.O>: JEFFERIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $30 VS $31
Reuters · 1d ago
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)?
Simply Wall St · 1d ago
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement
Simply Wall St · 2d ago
Weekly Report: what happened at GLUE last week (0316-0320)?
Weekly Report · 03/23 10:36
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Monte Rosa Therapeutics (GLUE) and Curis (CRIS)
TipRanks · 03/22 12:30
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback
Simply Wall St · 03/21 14:05
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.